Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
31 Mars 2023 - 7:30AM
Business Wire
- Scott D. Myers to step down as Chairman end Q1 2023
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 –
ALSEN) a pioneering clinical-stage biotechnology company which
specializes in gene therapies in the ear, announces the appointment
of Khalil Barrage as Interim Chair of the Board. Mr Barrage will
replace Scott D. Myers, who has informed the Board that he will
step down to manage other commitments, as he was recently appointed
as Chief Executive Officer of Viridian Therapeutics Inc.
Mr Barrage has served on the Board of Sensorion for over three
years, supporting with several capital raises and providing
leadership on the Company’s evolution towards becoming a gene
therapy-focused company. He has been a managing director at Invus
Group, a major investor in Sensorion, for nearly 20 years, heading
its Public Equity group and serves on the Boards of Elevate Bio,
Onxeo, Orthobond and Protagenic Therapeutics. He is also a Board
member of the Children of Armenia Fund and Solving Kids Cancer. Mr
Barrage holds a BA from the American University of Beirut.
Sensorion has commenced a search process to appoint a new
independent Chair of the Board and will provide an update in due
course.
Nawal Ouzren, Chief Executive Officer of Sensorion,
commented: “Scott has been an extremely effective and engaged
Chair at Sensorion and on behalf of the Board and management team,
I would like to extend my sincere thanks and wish him well going
forward.
“Khalil Barrage is a seasoned investment professional with
decades of experience investing in and supporting private and
public life sciences companies. We are delighted to have someone of
his calibre and who knows the Company so well, steering the
business as we evolve our focus into the promising area of gene
therapies for the ear.”
Khalil Barrage commented: “I also would like to thank
Scott for his immense contribution, he has provided expert
leadership as we have moved into the next stage of development with
a focus on gene therapy. Sensorion is a great Company with a highly
compelling proposition for creating durable solutions to address
inner ear disease. I’m very confident that the team can help
steward its promising programme of gene therapy assets into
clinical development.
“Sensorion is building an extremely high-quality leadership
team, recently appointing David Lawrence as our Chief Financial
Officer alongside Nawal. David has decades of experience in
financing, capital markets and business development. This is the
right team to move Sensorion and its innovative product candidates
forward and I’m excited to be working with them.”
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of gene therapies to restore hearing
loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary
monogenic forms of deafness, developed in the framework of its
broad strategic collaboration focused on the genetics of hearing
with the Institut Pasteur. OTOF-GT targets deafness caused by
mutations of the gene encoding for otoferlin and GJB2-GT targets
hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The
Company is also working on the identification of biomarkers to
improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small
molecule programs for the treatment and prevention of hearing loss
disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2
product: SENS-401 (Arazasetron) progressing in a planned Phase 2
proof of concept clinical study of SENS-401 in Cisplatin-Induced
Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of
SENS-401 in patients scheduled for cochlear implantation. A Phase 2
study of SENS-401 was also completed in Sudden Sensorineural
Hearing Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2022 full year financial report published on March 30, 2023, and
available on our website and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230330005724/en/
Investor Relations David Lawrence, Chief Financial
Officer (US/UK) Noémie Djokovic, Investor Relations and
Communications (Europe/France) ir.contact@sensorion-pharma.com
International Media Relations Consilium1Strategic
Communications Jessica Hodgson/Sue Stuart +44 7593 572720 +44 7561
424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024